Effects of P24 on Postprandial Aminoacidemia (NCT07479173) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effects of P24 on Postprandial Aminoacidemia
United States30 participantsStarted 2026-05-01
Plain-language summary
The purpose of this study is to quantify the acute effects of an acid-active protease enzyme supplement (P24) on postprandial aminoacidemia following consumption of a standardized mixed-protein meal containing both plant- and animal-derived protein sources. Secondary objectives include evaluating the postprandial plasma peptidomic response, characterizing the postprandial hormonal responses (GLP-1, insulin, and GIP), and assessing the postprandial glucose response using standardized capillary blood glucose measurements. The study will also evaluate subjective responses including satiety and hunger and gastrointestinal symptoms.
Who can participate
Age range
45 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy adults aged 45-75 years
* BMI 18.5-35 kg/m2
* Able to provide informed consent and comply with study procedure
* Willing to consume the standardized mixed-protein test meal
Exclusion Criteria:
* BMI outside of 18.5-35 kg/m2
* Gastrointestinal disorders or malabsorption syndromes that could affect digestion/absorption (e.g., inflammatory bowel disease, celiac disease)
* Diagnosed diabetes
* Current use of medications or supplements that materially affect glucose metabolism or digestion (e.g., GLP-1 receptor agonists, chronic digestive enzyme supplementation)
* Resting blood pressure ≥ 140/90 mmHg
* Self-reported cancer within past 5 years
* Known allergy or intolerance to meal components or capsule ingredients
* Self-reported anemia or other conditions that increase risk from blood draws
* Pregnancy or breastfeeding
* Current smoking or nicotine use, heavy alcohol use (defined as \> 5 drinks/day or \> 15 drinks/week), or other factors that in the investigator's judgment make participation unsafe
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Postprandial total amino acid incremental area under the curve after the test meal with P24 versus placebo
Timeframe: 0 to 180 minutes after meal consumption